Stock surges 98% in morning trading

  • Ambrx Biopharma shares double on $2B acquisition by Johnson & Johnson
  • Stock up 98% to $27.05 in morning trading
  • Shares have risen sixfold in the last year
  • Johnson & Johnson to pay $28 a share, representing a premium of 105%
  • Deal expected to have a value of $1.9 billion net of estimated cash required
  • Ambrx developing candidates for treating multiple types of cancer using synthetic biotechnology platform

Shares of Ambrx Biopharma surged Monday after the company agreed to be acquired by Johnson & Johnson for $2 billion in cash. The stock was up 98% to $27.05 in morning trading. Shares have risen sixfold in the last year. Johnson & Johnson will pay $28 a share, which Ambrx said represented a premium of 105% on the Jan. 5 closing price. The deal is expected to have a value of $1.9 billion net of estimated cash required. Ambrx is developing candidates for treating multiple types of cancer using a proprietary synthetic biotechnology platform.

Public Companies: Ambrx Biopharma (N/A), Johnson & Johnson (N/A)
Private Companies:
Key People:

Factuality Level: 8
Justification: The article provides factual information about the acquisition of Ambrx Biopharma by Johnson & Johnson, including the agreed-upon price, the increase in stock price, and the premium offered. It also mentions the value of the deal and provides a brief description of Ambrx’s focus on developing cancer treatments using a synthetic biotechnology platform. However, the article lacks additional context or analysis, and it does not provide any sources or quotes to support the information presented.

Noise Level: 3
Justification: The article provides relevant information about the acquisition of Ambrx Biopharma by Johnson & Johnson and the increase in stock price. However, it lacks in-depth analysis, scientific rigor, and evidence to support the claims made about the company’s technology and potential impact on cancer treatment.

Financial Relevance: Yes
Financial Markets Impacted: Shares of Ambrx Biopharma and Johnson & Johnson

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The news article pertains to a financial topic as it discusses the acquisition of Ambrx Biopharma by Johnson & Johnson for $2 billion in cash. There is no mention of an extreme event in the article.

Reported publicly: www.marketwatch.com